The Michigan Trauma Quality Improvement Program

Boyne Mountain, MI May 17, 2017



Disclosures

Salary Support for MTQIP from BCBSM/BCN

- Mark Hemmila
- Judy Mikhail
- Jill Jakubus
- Anne Cain-Nielsen

Evaluations

Paper

- This meeting only
- Turn in at end of day

Introductions

- Chris Tignanelli, MD
 - University of Michigan Surgical Critical Care Fellow
 - Grade 3 Liver Injuries
 - ACS-COT Activation Status
- Jerry Jurkovich, MD
 - Vice Chairman, Department of Surgery, UC Davis
 - Mo Henig Lecturer
- Todd Maxson, MD
 - ACS-COT VRC Chair
 - TMD Arkansas Children's Hospital

Introductions

- Mike Englesbe, MD
 - University of Michigan Transplant Surgeon
 - MSQC Co-director
 - Michigan OPEN
- Ben Jacobs
 - University of Michigan General Surgery Resident
 - EAST VTE Paper

Data Submission

Data submitted April 7, 2017

- DI 15 centers
- CDM 10 centers
- Lancet 1 center
- Available in ArborMetrix site on 5/3/2017
- Next data submission
 - June 2, 2017

Future Meetings

- Spring (Registrars and MCR's)
 - Tuesday June 6, 2017
 - Ann Arbor, NCRC
- Fall
 - Tuesday October 10, 2017
 - Ypsilanti, EMU Marriott
- Winter
 - Tuesday February 13, 2018
 - Ypsilanti, EMU Marriott

MTQIP/Orthopedic Surgery Meeting

Fall 2017

- Thursday October 26, 2017
- Rochester, MI
- Suggestions
 - Topics
 - Planning

Data Analytics Update

Jill Jakubus, PA-C MHSA



Meeting Reports

Contents

| Description of Cohorts | |
|-------------------------------------|---|
| Statistical Methods | |
| Mortality Graphs | 9 |
| Trends | |
| Outcomes | |
| Resource Utilization | |
| System Efficiency – New Section | |
| Process Measures | |
| CQI Performance Index – New Section | |

Dashboard

MTQIP Dashboard

M·TQIP

11/1/14 - 1/31/17 Cohort 2 Exclude DOA

| Outcome | Center | MTQIP | 95% CI |
|------------------------|--------|-------|--------|
| Failure to Rescue | | | |
| Superficial SSI | | | ŏ |
| Deep SSI | | | • |
| Organ/Space SSI | | | |
| Wound Disruption | | | |
| Abd. Fascia Left Open | | | |
| Acute Lung Injury/ARDS | | | |
| Pneumonia | | | • |

11/1/14 - 1/31/17 Cohort 2 Exclude DOA

| Mortality | Center | MTQIP | 95% CI |
|------------------------------------|--------|-------|--------|
| Dead | | | |
| Dead or Hospice | | | • |
| Cohort 2 (Admit to Trauma Service) | | | |
| Cohort 3 (Blunt Multi-System) | | | • |
| Cohort 4 (Blunt Single-System) | | | |
| Cohort 5 (Penetrating) | | | |
| Age16-24 | | | • |
| Age 25-44 | | | • |


M·TQIP

| PARTICIPATION POINTS | | | | | 3 |
|-------------------------------|----------------|----------------------------|---------------|-----------------------------|-----------------|
| Data Validation 2017 | 0 / 10 points | Data Submission | 0 / 10 points | Meeting Attendance | 3 / 10 points |
| | % | Feb submission | complete | Feb meeting | present |
| | | June submission | pending | May meeting | pending |
| | | Oct submission | pending | June meeting | pending |
| | | | | Oct meeting | pending |
| PERFORMANCE POINTS | | | | | 48.3 |
| VTE Prophy Timing ≤ 48 hrs | 10 / 10 points | VTE Prophy Type - LMWH | 7 / 10 points | RBC/FFP Ratio | 7.3 / 10 points |
| Admit to trauma - cohort 2 | | Admit to trauma - cohort 2 | | All - cohort 1 | |
| 1/1/16 - 1/31/17 | | 1/1/16 - 1/31/17 | | 1/1/16 - 1/31/17 | |
| Serious Complications Z-score | 7 / 10 points | Mortality Z-score | 7 / 10 points | IVC Filter Placement | 10 / 10 points |
| Admit to trauma - cohort 2 | | Admit to trauma - cohort 2 | | All - cohort 1 | |
| 7/1/14 - 1/31/17 | | 7/1/14 - 1/31/17 | | 7/1/16 - 1/31/17 | |
| | | | | Collaborative total | |
| PI Project | 0 / 10 points | | | | |

Met or exceeded target (10 pts) Improved, but did not meet target (7 pts) No improvement (0 pts)

TOTAL POINTS

New Video Resource



Analytics

| | COHORT |
|---|--|
| | Cohort 1 (All) |
| | Cohort 1 (All) |
| | Cohort 2 (Admit to Trauma Service) |
| 2 | Cohort 3 (Blunt Multi-System) |
| • | Cohort 4 (Blunt Single-System) |
| | Cohort 5 (Penetrating) |
| | Cohort 6 (Admit to non-Trauma Service) |
| | Cohort 7 (Benchmark) |

Cohort 8 (Isolated Hip Fracture)

Analytics

TQIP Isolated Hip Fractures (IHF):

- Age 65 years or older
- Injury mechanism of fall, derived from submitted External Cause Code
- At least one of the following AIS 98 codes:
 - o 851810.3 Femur, Fracture, Intertrochanteric
 - o 851812.3 Femur, Fracture, Neck
 - o 851818.3 Femur, Fracture, Subtrochanteric
 - o 853171.3 Femur, Fracture, Femoral head
- Any other injuries are in AIS external body region (i.e., bruise, abrasion, or laceration)

Updates – Complication Grades

- Reviewed by MTQIP Advisory Board
- Changes based on mortality and clinical acuity
- Implementation 7/1/17

| Complication | N died w Comp | N Comp Mortality | MTQIP Revise | MTQIP Serious | ACSTQIP | Change from |
|--------------------------------|------------------|------------------|-----------------|------------------|---------|----------------|
| Cardiac arrest | - | | 3 | Serious | Major | |
| Acute renal failure (dialysis) | | | 3 | Serious | Major | |
| ARDS | | | 3 | Serious | Major | |
| MI | | | 3 | Serious | Major | |
| Unplanned intubation | | | 3 | Serious | | 2 |
| Stroke/CVA | | | 3 | Serious | Major | |
| Systemic sepsis | | | 3 | Serious | Major | |
| Renal insufficiency | | | 3 | Serious | | None |
| Return to ICU | | | 2 | Serious | Major | 1 |
| Pneumonia | | | 2 | Serious | Major | |
| Return to OR | | | 2 | Serious | Major | |
| DVT UE | | | 2 | Serious | | |
| Decubitus ulcer | | | 2 | Serious | Major | |
| C. diff colitis | | | 2 | Serious | | 1 |
| Pulmonary embolism | | | 2 | Serious | Major | |
| DVT LE | | | 2 | Serious | 125 | |
| EC fistula | | | 2 | Serious | | |
| Extremity compartment syndrome | | | 2 | Serious | | |
| Superficial ssi | | | 1 | | | |
| Wound disruption | | | 1 | | | |
| Deep ssi | | | 1 | | Major | |
| CRBSI/CLABSI | | | 1 | | Major | |
| UTI | | | 1 | | | |
| Organ space ssi | | | 1 | | Major | |
| Alcohol or drug withdrawal | | | 1 | | | |
| Osteomyelitis | | | 1 | | | |
| Graft failure | | | exclude | | | 1 |
| Abdominal compartment syndrome | | | exclude | | | |
| Abdominal fascia left open | | | exclude | | | |

Updates – Remote Validation

| RAA Received | RAA Not Received |
|--------------|---|
| 1. | |
| 2. | |
| 3. | |
| 4. | 1 |
| 5. | |
| 6. | |
| 7. | |
| 8. | |
| 9. | |
| 10. | |
| 11. | |
| 12. | |
| 13. | |
| 14. | |
| 15. | |
| 16. | |
| 17. | |
| 18. | Due Oct 2, 2017 |
| 19. | \$2K withheld for non-receipt or inability to fulfill |

Resources

What does this cohort mean?



DATA RESOURCES

COHORT FORMATION

Cohort Formation Filter Index

DATA DICTIONARY

2017 MTQIP Data Dictionary - Variables and Definitions 2016 MTQIP Data Dictionary - Variables and Definitions 2015 MTQIP Data Dictionary - Variables and Definitions 2014 MTQIP Data Dictionary - Variables and Definitions 2013 MTQIP Data Dictionary - Variables and Definitions 2012 MTQIP Data Dictionary - Variables and Definitions

DATA ELEMENTS

2017 MTQIP Custom Data Elements 2016 MTQIP Custom Data Elements 2015 MTQIP Custom Data Elements 2014 MTQIP Custom Data Elements 2013 MTQIP Custom Data Elements 2012 MTQIP Custom Data Elements MTQIP Sample Report

Resources

What does this cohort mean?



Description of Cohorts

Cohort 1 (All)

- 1) Mechanism = Blunt or penetrating
- 2) Age \geq 18, Age \geq 16 starting 1/1/13
- 3) ISS ≥ 5
- 4) Hospital LOS ≥ 1 day or dead


Cohort 1 (All) w/o DOA's

- 1) Mechanism = Blunt or penetrating
- 2) Age \geq 18, Age \geq 16 starting 1/1/13
- 3) ISS ≥ 5
- 4) Hospital LOS ≥ 1 day or dead
- 5) Exclude patients who had no signs of life

2 (Admit trauma)

- 1) Mechanism = Blunt or penetrating
- Age ≥ 18, Age ≥ 16 starting 1/1/13
- 3) ISS ≥ 5
- 4) Hospital LOS ≥ 1 day or dead
- 5) Admit to trauma service if ED disposition not death

Resources




C. Diff Colitis

MTQIP Publications Update

Judy Mikhail, PhD





ADMINISTRATIVE RESOURCES



ADMINISTRATIVE RESOURCES

AGREEMENTS

Business Associate Agreement Data Use Agreement Data Use Agreement Attachment A Membership Application Form Remote Access Agreement

STAFFING

MCR Job Description MTQIP Emergency General Surgery Survey MTQIP Hospital Survey

PERFORMANCE INDEX

2017 Performance Index 2016 Performance Index 2015 Performance Index 2014 Performance Index 2013 Performance Index 2012 Performance Index 2011 Performance Index

EXPECTATIONS & POLICIES

Collaborative Expectations Confidentiality Statement Data Request Processing Guest Policy Publications Policy Publication Proposal Form Site Specific Project Form

PROCESSES

Data Standardization Process Data Validation Case Selection Data Validation Remote Data Validation On-Site


EXPECTATIONS & POLICIES

Collaborative Expectations Confidentiality Statement Data Request Processing Guest Policy Publications Policy Publication Proposal Form Site Specific Project Form

Research Proposal Form

| Date submitted | |
|---|---|
| Working title | |
| Study type | Research – Defined as systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. Quality Improvement – Defined as improvement activities as a systematic, data-guided activities designed to implement promising ways to improve clinical care, patient safety, and health care operations at the local setting. |
| IRB #/ name *Required for research study | |
| Researcher names/institution | |
| Working hypothesis | |
| Inclusion criteria | |
| Exclusion criteria | |
| Major outcomes | |
| Basic stat analysis outline | |

Data Request Processing Tree



MTQIP Publications Policy

<u>Committee</u>

- 1. David Share, MD (BCBSM)
- 2. John Kepros, MD
- 3. Wendy Wahl, MD
- 4. Judy Mikhail, PhD, RN

- Review abstracts
- Ensure consistency with MTQIP mission
- Manage any conflicts
- Recommend approval to Dr. Hemmila, Program Director

Liver Injuries Activation *Coming – December 2017*

Chris Tignanelli, MD



MTQIP Data


Mark Hemmila, MD



#4 VTE Prophylaxis Initiated ≤ 48 hrs


Website

- Practices > VTE Prophylaxis Metric
- Cohort = Cohort 2 (admit to Trauma)
- No Signs of Life = Exclude DOAs
- Transfers Out = Exclude Transfers Out
- Default Period = Set for CQI Index time period
- Heparin, LMWH <= 48 Hours</p>
 - Hospital Unadj %



1/1/16-1/31/17

Percent




Timely VTE Prophylaxis


%

#5 VTE Prophylaxis with LMWH

Website


- Practices > VTE Prophylaxis Type
- Cohort = Cohort 2 (admit to Trauma)
- No Signs of Life = Exclude DOAs
- Transfers Out = Exclude Transfers Out
- Default Period = Set for CQI Index time period
- LMWH (Type)
 - Hospital Unadj %





1/1/16-1/31/17

Percent




Type VTE Prophylaxis

Year

MTQIP VTE Prophylaxis

- VTE
 - VTE Rate
 - Begin = 2.5 %
 - Previous = 1.3 %
 - Current = 1.3 %
 - Target = 1.5 %
 - 48 hr VTE Prophylaxis Rate
 - Begin = 38 %
 - Previous = 59 %
 - Current = 61 %
 - Target = 50 %



² 20⁹ 20¹⁰ 20¹¹ 20¹² 20¹² 20¹⁴ 20¹⁵ 20¹⁵ 20¹⁵


Year

%

2008

MTQIP VTE Prophylaxis

- VTE
 - VTE Rate
 - Begin = 2.5 %
 - Previous = 1.3 %
 - Current = 1.3 %
 - Target = 1.5 %
 - VTE Prophylaxis with LMWH
 - Begin = 27 %
 - Previous = 41 %
 - Current = 43 %
 - Target = 50 %



Year

#6 PRBC to Plasma ratio in Resuscitation

Website

- Practices > Hemorrhage
- Cohort = Cohort 1
- No Signs of Life = Include DOAs
- Transfers Out = Include Transfers Out
- Default Period = Set for CQI Index time period
- N, Eligible patients
 - List
 - PRBC/FFP Ratio

MTQIP 2016 Collaborative-Wide PI Projects


- Hemorrhage (\geq 5 u PRBC's first 4 hrs)
 - 1/1/2016 to 1/31/2017
 - % of patients with 4hr PRBC/FFP ratio ≤ 2.5
 - 2013 = 65 %
 - Current = 85 % (190/223)
 - % of patients with 4hr PRBC/FFP ratio ≤ 2.0
 - 2013 = 55 %
 - Current = **79 %** (177/223)
 - Target = 80 %

Massive Transfusion Ratio

- Massive Transfusion
 - \geq 5 units PRBC's in first 4 hrs
 - Average of tier points score for each patient
 - 0 units FFP places patient in tier 4
 - 3/1/14 5/31/16

| Ratio PRBC/FFP | Tier | Points |
|-------------------|------|--------|
| < 1.5 | 1 | 10 |
| 1.6 – 2.0 | 2 | 10 |
| 2.1 – 2.5 | 3 | 5 |
| > 2.5 | 4 | 0 |

Blood Product Ratio Points if ≥ 5 uPRBCs 1/1/16 - 4/1/17



POP QUIZ

Ventilator Days

Patient is trached, continuously on ventilator in CPAP mode with pressure support of 10, PEEP 5, FiO2 60%

Ventilator Days

Is this counted as a ventilator day?

TOTAL VENTILATOR DAYS

The cumulative amount of time spent on the ventilator. Each partial or full day should be measured as one calendar day.

Excludes mechanical ventilation time associated with OR procedures.

Non-invasive means of ventilatory support (CPAP or BIPAP) should not be considered in the calculation of ventilator days.

- Recorded in full day increments with any partial calendar day counted as a full calendar day.
- The calculation assumes that the date and time of starting and stopping Ventilator episode are recorded in the patient's chart.
- The null value "Not Known/Not Recorded" is used if any dates are missing.
- At no time should the Total Vent Days exceed the Hospital LOS.
- The null value "Not Applicable" is used if the patient was not on the ventilator according to the above definition.

ANSWER: YES

Z-score


- Measure of trend in outcome over time
- Hospital specific
 - Compared to yourself
- Standard deviation
- >1 getting worse
- 1 to -1 flat
- < -1 getting better

Z-score

- Time: 7/1/2014 to 1/31/17
- Cohort 2
- Exclude if no signs of life
- Exclude transfers out


#7 Serious Complication Rate (Z-score)

Z-score - Serious Complication Rate 7/1/14 - 1/31/17



8 Mortality Rate (Z-score)

Z-score - Mortality Rate 7/1/14 - 1/31/17




#9 IVC Filter Use

Website

- Practices > IVC Summary
- Cohort = Cohort 1
- No Signs of Life = Exclude DOAs
- Transfers Out = Exclude Transfers Out
- Default Period = Set for CQI Index time period
- IVC Filter Use
 - Group Unadj %


Unadjusted IVC Filter Use 7/1/16 - 1/31/17



7/1/16 - 1/31/17

Pg. 43

Unadjusted IVC Filter Use 11/1/14 - 1/31/17




1/1/14 - 1/31/17


Pg. 43

MTQIP Outcomes


Web-Site Report


- 11/1/2014 to 1/31/2017
- Rates
 - Risk and Reliability-adjusted
 - Red dash line is collaborative mean
- Legend
 - Low-outlier status (better performance)
 - Non-outlier status (average performance)
 - High-outlier status (worse performance)





Consortium Outcomes Overview Serious Cx






Mortality or Hospice (Cohort 1 w/o DOA's)


Pg. 15

Hospice Deaths (Cohort1)




Admit to Trauma Service






Admit to Trauma Service

Failure to Rescue




Pg. 26

DVT/Pulmonary Embolus




Pg. 28

VTE Prophylaxis Timing < 48 hrs 1/1/16 - 1/31/17




Percent






Percent

C. Difficile Colitis



Pg. 25

Adjusted Antibiotic Days



Trauma Center

State of Michigan

Proposal submitted and verbally accepted

Scope

- Level 1 and 2
 - Data submission
 - Reporting: Center, State, Region
 - Education
- Level 3
 - Data submission
 - Report development
 - Education
- EMS Data

Panel Discussion

Jerry Jurkovich, MD Todd Maxson, MD Amy Koestner, RN



Break

Back at 3:30 pm




ACS-TQIP Michigan Report


Mark Hemmila



Risk-Adjusted Mortality by Cohort TQIP Report ID: Michigan




Patient Cohort




Risk-Adjusted Mortality by Cohort - Spring 2017 TQIP Report ID: Michigan


Patient Cohort



Odds Ratios by TQIP Hospital; Mortality



Report



Report

What we know?

- Michigan, less sick
- AIS 2005/08 is crosswalked to AIS98
- Lagging patients are included
- Lot's of hospice
- DNR/Advance directive
 - Dropped
 - 85% live in MTQIP data
- Analyst (Anne)
 - Problems CI, size of centers

Table 1: Patient Inclusion by Month and Year

| Month and Year | NTDB (N) | TQIP (N) | TQIP (%) |
|----------------|-------------|-------------|-------------|
| January 2015 | 2,707 | 19 | 0.7 |
| February 2015 | 2,185 | 9 | 0.4 |
| March 2015 | 2,407 | 2 | 0.1 |
| April 2015 | 2,422 | 21 | 0.9 |
| May 2015 | 2,942 | 12 | 0.4 |
| June 2015 | 2,863 | 0 | 0.0 |
| July 2015 | 3,249 | 69 | 2.1 |
| August 2015 | 3,161 | 102 | 3.2 |
| September 2015 | 2,803 | 111 | 4.0 |
| October 2015 | 2,914 | 1,244 | 42.7 |
| November 2015 | 2,387 | 1,043 | 43.7 |
| December 2015 | 2,288 | 985 | 43.1 |
| January 2016 | 2,815 | 1,154 | 41.0 |
| February 2016 | 2,849 | 1,164 | 40.9 |
| March 2016 | 2,808 | 1,146 | 40.8 |
| April 2016 | 3,026 | 1,162 | 38.4 |
| May 2016 | 3,614 | 1,383 | 38.3 |
| June 2016 | 3,649 | 1,428 | 39.1 |

| Month and Year | NTDB (N) | TQIP (N) | TQIP (%) |
|----------------|-------------|-------------|-------------|
| July 2016 | 3,180 | 1,308 | 41.1 |
| August 2016 | 2,850 | 1,163 | 40.8 |
| September 2016 | 2,368 | 1,037 | 43.8 |

List of Patients

- Requested from ACS-TQIP
 - Your DUA does not allow
 - How could we change?
- U of M
 - Obtained off NTDB/TQIP report site
 - Matched to MTQIP data
- Request from centers
 - 5 CQI points, by July 7
 - Benchmark report
 - Patient list

2018 CQI Scoring

Mark Hemmila



CQI Scoring

Approach

- Generate ideas
- Advisory committee
- Suggestion to change target
- Suggestion to add
- Suggestions to drop

Timing

- Finalize CQI scoring index at May meeting
- July 1, 2017 start

| | | | Trauma Quality Improvement P mance Index January 1, 2017 to | December 31, 2017 | |
|---------|-----------|--|--|---|--------|
| Measure | Weight | | Measure Description | on | Points |
| #1 | 10 | Data Submission (I | Partial/Incomplete Submissions N | lo Points) | |
| | | On time and compl | lete 3 of 3 times | | 10 |
| | | On time and comp | lete 2 of 3 times | | 5 |
| | | On time and comp | lete 1 of 3 times | | 0 |
| #2 | 10 | Meeting Participat | ion All Disciplines *Surgeon repr | esents 1 hospital only | |
| | | Surgeon, and (TPM | or MCR) Participate in 3 of 3 Coll | aborative meetings (9 pts) | 0-10 |
| | | Surgeon, and (TPM | or MCR) Participate in 2 of 3 Coll | aborative meetings (6 pts) | |
| | | Surgeon, and (TPM | or MCR) Participate in 1 of 3 Coll | aborative meetings (3 pts) | |
| | | Surgeon, and (TPM | or MCR) Participate in 0 of 3 Coll | aborative meetings (0 pts) | |
| | | Registrar, and/or N | ICR Participate in the Data Abstra | ctor Meeting (1 pt) | |
| #3 | 10 | Data Accuracy | 1st Validation Visit-Error Rate | 2 Validation Visits-Error Rate | |
| | | 5 Star Validation | 0-4.5% | 0-4.0% | 10 |
| | | 4 Star Validation | 4.6-5.5% | 4.1-5.0% | 8 |
| | | 3 Star Validation | 5.6-8.0% | 5.1-6.0% | 5 |
| | | 2 Star Validation | 8.1-9.0% | 6.1-7.0% | 3 |
| | | 1 Star Validation | >9.0% | >7.0% | 0 |
| #4 | 10 | Venous Thromboe | mbolism (VTE) Prophylaxis Initiat | ted Within 48 Hours of Arrival in | |
| | 12.004.00 | - 198 September 1990 Concerns and the | mits with ≥ 2 Day Length of Stay | | |
| | | ≥ 50% | · · · · · · · · · · · · · · · · · · · | | 10 |
| | | ≥ 40% | | | 5 |
| | | < 40% | | | 0 |
| #5 | 10 | Low Molecular We | ight Heparin (LMWH) Venous Th | romboembolism (VTE) | |
| | 5.202.0 | - 이상 이가, 아님, 같은 것을 잘 받았다. 한 것을 것 같아요? | Trauma Service Admits (18 Mo's | | |
| | | ≥ 50% | | | 10 |
| | | 21-49% | | | 7 |
| | | 5-20% | | | 5 |
| | | < 5% | | | õ |
| #6 | 10 | 100/01/200 | Plasma Ratio (Weighted Mean Po | ints) of Patients Transfused >5 | |
| 10 | 10 | | s (18 Mo's: 1/1/16-6/30/17) | intaj of Futicitis Humanascu <u>s</u> o | |
| | | 10 pts: Tier 1: < 1.5 | | | 0-10 |
| | | 10 pts: Tier 2: 1.6-2 | | | 0.10 |
| | | 5 pts: Tier 3: 2.1-2 | | | |
| | | 0 pts: Tier 4: >2.5 | | | |
| #7 | 10 | | on Rate-Trauma Service Admits (| 2 10 200 7/1 /14 6/20/17) | |
| #/ | 10 | 2 - CARLON CONTRACTOR (CARLON) | 이 같은 것 않는 것 같이 없는 것을 입니다. 것 같은 것 같 | 5 years: //1/14-0/50/17) | 10 |
| | | Z-score: < -1 (majo | erious complications low-outlier | (| 10 |
| | | | ~ 그 방법은 지원은 동안은 그 것은 것이라. 이 것은 것도 것 같아요. 그는 것은 것은 것이라는 것이라. 것이다. 것 | | 7 |
| #0 | 10 | | of serious complications increased uma Service Admits (3 years: 7/1 | | 2 |
| #8 | 10 | 57 C 46C 1822 7 3 2 1 0 C 47 5 1 1 | | ./14-0/30/17) | 10 |
| | | Z-score: < -1 (majo | | | 10 |
| | | | mortality low-outlier (average or b | oetter rate) | 7 |
| 40 | 10 | | of mortality increased) | | 5 |
| #9 | 10 | 107 CON | Filter Use (All Admits) (Collabora | ative Wide) (//1/16-6/30/1/) | 10250 |
| | | ≤1.2 | | | 10 |
| #10 | 10 | >1.2 | | 6 December 2017 | 0 |
| #10 | 10 | Provide and the second second second | y Improvement Project (July 201 | to-December 2017) | |
| | | and the second sec | met or exceeded target | 92. S | 10 |
| | | | wed improvement, but did not me | et target | 7 |
| | | implemented, but | showed no improvement | | 0 |
| | | | | Total (Max Points) = | 100 |

| | | 2017 Performance | Index January 1, 2017 to | | | |
|---------|----------|---|---|----------------------------------|-----------|---|
| Measure | Weight | | Measure Description | on | Points | |
| #1 | 10 | Data Submission (Partial, | Incomplete Submissions N | Io Points) | | 1 |
| | | On time and complete 3 of 3 times | | | 10 | |
| | | On time and complete 2 of | | | 5 | |
| 0.051 | | On time and complete 1 of | | | 0 | |
| #2 | 10 | Meeting Participation All | Disciplines *Surgeon repr | esents 1 hospital only | 201100001 | ſ |
| | | Surgeon, and (TPM or MC | R) Participate in 3 of 3 Coll | aborative meetings (9 pts) | 0-10 | |
| | | | R) Participate in 2 of 3 Coll | | | |
| | | | R) Participate in 1 of 3 Coll | | | |
| | | Surgeon, and (TPM or MC | R) Participate in 0 of 3 Coll | aborative meetings (0 pts) | | |
| | | | rticipate in the Data Abstra | | | |
| #3 | 10 | Data Accuracy 1st V | alidation Visit-Error Rate | 2 Validation Visits-Error Rate | | 1 |
| | | 5 Star Validation | 0-4.5% | 0-4.0% | 10 | |
| | | 4 Star Validation | 4.5.5.5% | 4.1-5.0% | 8 | |
| | | 3 Star Validation | 5.6-8.0% | 5.1-6.0% | 5 | L |
| | | 2 Star Validation | 8.1-9.0% | 6.1-7.0% | 3 | |
| | | 1 Star Validation | >9.0% | >7.0% | 0 | |
| #4 | 10 | Venous Thromboembolis | m (VTE) Prophylaxis Initiat | ed Within 48 Hours of Arrival in | | |
| | | Trauma Service Admits w | ith ≥ 2 Day Length of Stay | (18 Mo's: 1/1/16-6/30/17) | | |
| | | ≥ 50% | | | 10 | |
| | | ≥ 40% | | | 5 | |
| | | < 40% | | | 0 | |
| #5 | 10 | Low Molecular Weight H | eparin (LMWH) Venous Th | romboembolism (VTE) | | 1 |
| | | Prophylaxis Use in Traum | a Service Admits (18 Mo's | : 1/1/16-6/30/17) | | |
| | | ≥ 50% | | | 10 | |
| | | 21-49% | | | 7 | |
| | | 5-20% | | | 5 | |
| | | < 5% | | | 0 | l |
| #6 | 10 | Red Blood Cell to Plasma | Ratio (Weighted Mean Po | ints) of Patients Transfused >5 | | 1 |
| | | Units in 1st 4 Hours (18 N | Ao's: 1/1/16-6/30/17) | | | |
| | | 10 pts: Tier 1: ≤ 1.5 | | | 0-10 | |
| | | 10 pts: Tier 2: 1.6-2.0 | | | | |
| | | 5 pts: Tier 3: 2.1-2.5 | | | | |
| | | 0 pts: Tier 4: >2.5 | | | | |
| #7 | 10 | Serious Complication Rat | e-Trauma Service Admits (| 3 years: 7/1/14-6/30/17) | | 1 |
| | 20280-01 | Z-score: < -1 (major impro | ovement) | | 10 | |
| | | Z-score: -1 to 1 or serious | complications low-outlier | (average or better rate) | 7 | |
| | | Z-score: > 1 (rates of serio | ous complications increased | 1) | 5 | |
| #8 | 10 | Mortality Rate-Trauma S | ervice Admits (3 years: 7/1 | /14-6/30/17) | | 1 |
| | | Z-score: < -1 (major impro | ovement) | | 10 | |
| | | | ty low-outlier (average or b | etter rate) | 7 | |
| | | Z-score: > 1 (rates of mor | | | 5 | |
| #9 | 10 | | | ative Wide) (7/1/16-6/30/17) | | 1 |
| | | ≤1.2 | | | 10 | |
| | | >1.2 | | | 0 | |
| #10 | 10 | | ovement Project (July 201 | 6-December 2017) | <u> </u> | 1 |
| 1922 | 2333 | Implemented, and met or | 이상 날에서는 것은 것이 집에 집에 집에서 집에 집에 많이 많이 했다. | | 10 | |
| | | The second se | provement, but did not me | et target | 7 | |
| | | Implemented, but showe | | | o | |
| | | | | Total (Max Points) = | 100 | + |

| | | Michigan Trauma Quality Improvement Program (MTQIP) 2017 Performance Index January 1, 2017 to December 31, 20 | 17 | | |
|---------|--------|--|---|---------|-------|
| Measure | Weight | Measure Description | | Points | Γ |
| #1 | 10 | Data Submission (Partial/Incomplete Submissions No Points) | 18 | | C. |
| 107 | | On time and complete 3 of 3 times | | 10 | |
| | | On time and complete 2 of 3 times | | 5 | |
| | | On time and complete 1 of 3 times | | õ | |
| #2 | 10 | Meeting Participation All Disciplines *Surgeon represents 1 hospita | only | - | |
| 112 | -10 | Surgeon, and (TPM or MCR) Participate in 3 of 3 Collaborative meetin | | 0-10 | |
| | | Surgeon, and (TPM or MCR) Participate in 2 of 3 Collaborative meetin | | 0 10 | |
| | | Surgeon, and (TPM or MCR) Participate in 1 of 3 Collaborative meetin | F1000 1000 | | 3 |
| | | Surgeon, and (TPM or MCR) Participate in 0 of 3 Collaborative meetin | Z-60.001 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 1210 - 12 | | NA12 |
| | | Registrar, and/or MCR Participate in the Data Abstractor Meeting (1 p | | | 1 |
| #3 | 10 | | Visits-Error Rate | | 1 |
| 110 | 10 | | 1.0% | 10 | 1 |
| | | | -5.0% | 8 | |
| | | | -6.0% | 5 | |
| | | | 7.0% | 3 | |
| | | | .0% | õ | |
| #4 | 10 | Venous Thromboembolism (VTE) Prophylaxis Initiated Within 48 Ho | | v | |
| 11.4 | 10 | Trauma Service Admits with ≥ 2 Day Length of Stay (18 Mo's: $1/1/16$ | Contraction of the strength of the second | | |
| | | ≥ 50% | -0/30/17/ | 10 | |
| | | ≥ 30% ≥ 40% | | 5 | |
| | | < 40% | | 0 | |
| #5 | 10 | 40% Low Molecular Weight Heparin (LMWH) Venous Thromboembolism | | U | |
| #D | 10 | Prophylaxis Use in Trauma Service Admits (18 Mo's: 1/1/16-6/30/17 | | | |
| | | | , | 10 | |
| | | ≥ 50% | | 10 | |
| | | 21-49% | | 7 | |
| | | 5-20% | | 5 | |
| | | < 5% | | 0 | |
| #6 | 10 | Red Blood Cell to Plasma Ratio (Weighted Mean Points) of Patients | Transfused 25 | | |
| | | Units in 1st 4 Hours (18 Mo's: 1/1/16-6/30/17) | | | A set |
| | | 10 pts: Tier 1: ≤ 1.5 | | 0-10 | |
| | | 10 pts: Tier 2: 1.6-2.0 | | | 100 |
| | | 5 pts: Tier 3: 2.1-2.5 | | | |
| | | 0 pts: Tier 4: >2.5 | | | |
| #7 | 10 | Serious Complication Rate-Trauma Service Admits (3 years: 7/1/14- | 5/30/17) | | |
| | | Z-score: < -1 (major improvement) | 1685 | 10 | 3 |
| | | Z-score: -1 to 1 or serious complications low-outlier (average or bette | r rate) | 7 | 10 |
| | | Z-score: > 1 (rates of serious complications increased) | 5044C | 5 | |
| #8 | 10 | Mortality Rate-Trauma Service Admits (3 years: 7/1/14-6/30/17) | 22 | 1014000 | 1 |
| | | Z-score: < -1 (major improvement) | | 10 | |
| | | Z-score: -1 to 1 or mortality low-outlier (average or better rate) | | 7 | |
| | | Z-score: > 1 (rates of mortality increased) | A | 5 | |
| #9 | 10 | Inferior Vena Cava Filter Use (All Admits) (Collaborative Wide) (7/1/ | 16-6/30/17) | 1021021 | |
| | | ≤1.2 | | 10 | |
| | | >1.2 | 0. | 0 | |
| #10 | 10 | Site Specific Quality Improvement Project (July 2016-December 201 | 7) | | |
| | ~~~~ | Implemented, and met or exceeded target | | 10 | |
| | | Implemented, showed improvement, but did not meet target | | 7 | |
| | | Implemented, but showed no improvement | 32 | 0 | |
| | | To | tal (Max Points) = | 100 | |

| | | | uma Quality Improvement P nee Index January 1, 2017 to | 수가 아프 방법 이는 것 같아요. 요즘 것 것 같아요. 같은 것 같아요. 같은 것 같아요. 같이 많이 | | |
|---------|---------|---|---|--|----------|----------------------------------|
| Measure | Weight | Contraction in the | Measure Descriptio | | Points | 1 |
| #1 | 10 | Data Submission (Part | al/Incomplete Submissions I | | | 6 |
| | 12/2020 | On time and complete | 승규야 다 가장 같은 것은 것을 가지 않는 것을 하는 것을 하는 것을 하는 것을 하는 것을 하는 것을 했다. | | 10 | |
| | | On time and complete | | | 5 | |
| | | On time and complete | | | 0 | |
| #2 | 10 | | Aeeting Participation All Disciplines *Surgeon represents 1 hospital only | | | |
| | | | WCR) Participate in 3 of 3 Coll | 그 집에 다 양 그 것을 알았는 것이 것 것 것 것 같아. 이 것 같아요. 한 것 같아요. | 0-10 | Contraction of the second second |
| | | | MCR) Participate in 2 of 3 Coll | | 2002.00 | |
| | | Surgeon, and (TPM or I | MCR) Participate in 1 of 3 Coll | aborative meetings (3 pts) | | |
| | | Surgeon, and (TPM or I | MCR) Participate in 0 of 3 Coll | aborative meetings (0 pts) | | |
| | | Registrar, and/or MCR | Participate in the Data Abstra | ctor Meeting (1 pt) | | |
| #3 | 10 | | Validation Visit-Error Rate | >2 Validation Visits-Error Rate | 3 | |
| | | 5 Star Validation | 0-4.5% | 0-4.0% | 10 | 1 |
| | | 4 Star Validation | 4.5.5.5% | 4.1-5.0% | 8 | |
| | | 3 Star Validation | 5.6-8.0 | 5.1-6.0% | 5 | |
| | | 2 Star Validation | 8.1-9.0% | 6.1-7.0% | 3 | |
| | | 1 Star Validation | >9.0% | >7.0% | 0 | |
| #4 | 10 | | | ted Within 48 Hours of Arrival in | | 6 |
| | 1000000 | | s with ≥ 2 Day Length of Stay | | | |
| | / | ≥ 50% | | | 10 | |
| | | ≥ 40% | | | 5 | |
| | | < 40% | | | 0 | |
| #5 | 10 | Low Molecular Weight | Heparin (LMWH) Venous Th | romboembolism (VTE) | | |
| | 0.00500 | | uma Service Admits (18 Mo's | | | |
| | | ≥ 50% | | | 10 | |
| | | 21-49% | | | 7 | |
| | | 5-20% | | | 5 | |
| | | < 5% | | | 0 | |
| #6 | 10 | Red Blood Cell to Plass | na Ratio (Weighted Mean Po | ints) of Patients Transfused ≥5 | | 1 |
| | 3036497 | | 8 Mo's: 1/1/16-6/30/17) | | | 1 |
| | | 10 pts: Tier 1: < 1.5 | | | 0-10 | |
| | | 10 pts: Tier 2: 1.6-2.0 | | | | Ì |
| | | 5 pts: Tier 3: 2.1-2.5 | | | | 1 |
| | | 0 pts: Tier 4: >2.5 | | | | |
| #7 | 10 | Serious Complication F | Rate-Trauma Service Admits (| 3 years: 7/1/14-6/30/17) | | |
| | 2538533 | Z-score: < -1 (major im | 그렇는 괜한 것 없어야 한 것을 입자 안 것 것 같아요. 것 것 것 것 것 같아? | | 10 | |
| | | The second se | us complications low-outlier | (average or better rate) | 7 | 1 |
| | | | rious complications increased | | 5 | |
| #8 | 10 | | Service Admits (3 years: 7/1 | | | |
| | 0.0200 | Z-score: < -1 (major im | | | 10 | |
| | | | ality low-outlier (average or I | petter rate) | 7 | |
| | | Z-score: > 1 (rates of m | | | 5 | |
| #9 | 10 | | | ative Wide) (7/1/16-6/30/17) | | 1 |
| | | ≤1.2 | | | 10 | |
| | | >1.2 | | | 0 | |
| #10 | 10 | | provement Project (July 201 | l6-December 2017) | <u> </u> | 1 |
| 1922 | SSA | Implemented, and met | | ····· | 10 | |
| | | 1. St. C. St. St. St. St. St. St. St. St. St. St | improvement, but did not me | et target | 7 | |
| | | Implemented, but show | | | o | |
| | | | | | | 1 |

≥ 50% 10 37-49% 7 25-36% 5 20-24% 3 <20% 0

| | | 2017 Perfor | mance Index January 1, 2017 to | | | |
|---------|---------|---|--|--|----------|----|
| Measure | Weight | | Measure Description | on | Points | |
| #1 | 10 | Data Submission (| Partial/Incomplete Submissions I | No Points) | 8 | 1 |
| | | On time and comp | lete 3 of 3 times | | 10 | |
| | | On time and comp | lete 2 of 3 times | | 5 | |
| | | On time and comp | lete 1 of 3 times | | 0 | |
| #2 | 10 | Meeting Participat | tion All Disciplines *Surgeon repr | resents 1 hospital only | | 1 |
| | | | l or MCR) Participate in 3 of 3 Coll | 이 집에 다 가 가 많을 것 같아. 그 집에 집에 가지 않는 것을 많은 것 같아요. | 0-10 | |
| | | | l or MCR) Participate in 2 of 3 Coll | | 24049765 | |
| | | | l or MCR) Participate in 1 of 3 Coll | 그 같은 것 같은 | | |
| | | Surgeon, and (TPN | l or MCR) Participate in 0 of 3 Coll | aborative meetings (0 pts) | | |
| | | 193 B CA 24 18 193 | ACR Participate in the Data Abstra | | | |
| #3 | 10 | Data Accuracy | The Validation Visit-Error Rate | >2 Validation Visits-Error Rate | 8 | 1 |
| | | 5 Star Validation | 0-4.5% | 0-4.0% | 10 | |
| | | 4 Star Validation | 4.5.5% | 4.1-5.0% | 8 | |
| | | 3 Star Validation | 5.6-8.0% | 5.1-6.0% | 5 | |
| | | | 8.1-9.0% | | 187 | |
| | | 2 Star Validation | Structure: | 6.1-7.0% | 3 | |
| | 10 | 1 Star Validation | >9.0% | >7.0% | U | + |
| #4 | 10 | | mbolism (VTE) Prophylaxis Initia | | | 1 |
| | | | Imits with ≥ 2 Day Length of Stay | (18 Mo's: 1/1/16-6/30/17) | | |
| | | ≥ 50% | | | 10 | |
| | | ≥ 40% | | | 5 | |
| | | < 40% | | | 0 | |
| #5 | 10 | | eight Heparin (LMWH) Venous Th | | 8 | t |
| | | Frophylaxis Use in | Trauma Service Admits (18 Mo's | : 1/1/16-6/30/17) | | |
| | | ≥ 50% | | | 10 | |
| | | 21-49% | | | 7 | |
| | | 5-20% | | | 5 | |
| | | < 5% | | | 0 | |
| #6 | 10 | Red Blood Cell to I | Plasma Ratio (Weighted Mean Po | ints) of Patients Transfused >5 | | 1 |
| | 2036202 | | rs (18 Mo's: 1/1/16-6/30/17) | | | |
| | | 10 pts: Tier 1: < 1.5 | | | 0-10 | |
| | | 10 pts: Tier 2: 1.6-2 | | | | |
| | | 5 pts: Tier 3: 2.1-2 | | | | |
| | | 0 pts: Tier 4: >2.5 | | | | I |
| #7 | 10 | | ion Rate-Trauma Service Admits (| 2 years 7/1/14 6/20/17) | 8 | 1 |
| #/ | 10 | 2012/01/01/01/01/01/01/07/07/2012/01/2 | 이는 아님들 뒤집에 잘 못했는 것 옷을 잡다 안 걸 것이다. 동안감 전한 다음 것을 했다. | 5 years. //1/14-0/50/17/ | 10 | |
| | | Z-score: < -1 (majo | 1 | (| 10 | |
| | | | serious complications low-outlier | | 7 | |
| | | | of serious complications increased | | 5 | - |
| #8 | 10 | - 25 g. (10) S. (10) (20) (20) (20) (20) (20) | uma Service Admits (3 years: 7/1 | 1/14-6/30/1/) | 01477 | |
| | | Z-score: < -1 (majo | | | 10 | |
| | | | mortality low-outlier (average or l | better rate) | 7 | |
| | | Z-score: > 1 (rates | of mortality increased) | | 5 | Į. |
| #9 | 10 | Inferior Vena Cava | Filter Use (All Admits) (Collabora | ativ <u>e Wide</u>) (7/1/16-6/30/17) | 10000 M | |
| | | ≤1.2 | Maintonanco | | 10 | |
| | 2 | >1.2 | Maintenance | | 0 | |
| #10 | 10 | Site Specific Quali | ty Improvement Project (July 20) | to-December 2017) | | |
| | ~50 | | met or exceeded target | | 10 | |
| | | | wed improvement, but did not me | eet target | 7 | |
| | e | | showed no improvement | | 0 | |
| | | | | Total (Max Points) = | 100 | t |

≥ 50% 10 37-49% 7 25-36% 5 20-24% 3 <20% 0

| | | 2017 Performance Index January 1, | | | _ |
|---------|---------|--|---|--------|---|
| Measure | Weight | Measure D | Description | Points | |
| #1 | 10 | Data Submission (Partial/Incomplete Subm | nissions No Points) | -19 | 1 |
| | | On time and complete 3 of 3 times | | 10 | |
| | | On time and complete 2 of 3 times | | 5 | |
| 0.0001 | | On time and complete 1 of 3 times | the main result in the second se | 0 | |
| #2 | 10 | Meeting Participation All Disciplines *Surg | eon represents 1 hospital only | . 0.9 | |
| | | Surgeon, and (TPM or MCR) Participate in 3 | of 3 Collaborative meetings (9 pts) | 0-10 | |
| | | Surgeon, and (TPM or MCR) Participate in 2 | of 3 Collaborative meetings (6 pts) | | |
| | | Surgeon, and (TPM or MCR) Participate in 1 | of 3 Collaborative meetings (3 pts) | | |
| | | Surgeon, and (TPM or MCR) Participate in 0 | of 3 Collaborative meetings (0 pts) | | |
| | | Registrar, and/or MCR Participate in the Dat | ta Abstractor Meeting (1 pt) | | |
| #3 | 10 | Data Accuracy Int Validation Visit-Erro | or Rate 22 Validation Visits-Error Rate | 199 | 1 |
| | | 5 Star Validation 0-4.5% | 0-4.0% | 10 | |
| | | 4 Star Validation 4.5.5.5% | 4.1-5.0% | 8 | |
| | | 3 Star Validation 5.6-8.0X | 5.1-6.0% | 5 | |
| | | 2 Star Validation 8.1-9.0% | 6.1-7.0% | 3 | |
| | | 1 Star Validation >9.0% | >7.0% | 0 | |
| #4 | 10 | Vanous Thromboembolism (VTE) Prophyla | xis Initiated Within 48 Hours of Arrival in | 18 | t |
| | | Trauma Service Admits with ≥ 2 Day Length | | | |
| | / | ≥ 50% | | 10 | |
| | | ≥ 40% | | 5 | |
| | | < 40% | | 0 | |
| #5 | 10 | Low Molecular Weight Heparin (LMWH) Ve | nous Thromboembolism (VTE) | 19 | 1 |
| | 5.325.0 | Tophylaxis Use in Trauma Service Admits | 한 것은 것은 것을 위해 가지 않는 것을 것을 위해 있는 것을 수 있다. 이상 가지 않는 것은 아이가 지않는 것을 수 있다. 것을 가지 않는 것을 수 있다. 것을 하는 것은 것을 하는 것을 하는 것을 수 있다. 것을 하는 것을 하는 것을 수 있다. 것을 하는 것을 수 있다. 가지 않는 것을 수 있다. 것을 하는 것을 수 있다. 것을 수 있다. 것을 하는 것을 수 있다. 것을 수 있다. 가지 않는 것을 수 있다. 것을 수 있다. 가지 않는 것을 수 있다. 것을 것을 수 있다. 않다. 것을 수 있다. 않다. 것을 수 있다. 않다. 않다. 않다. 않다. 않다. 않다. 않다. 않다. 않다. 않 | | |
| | | ≥ 50% | (| 10 | |
| | | 21-49% | | 7 | I |
| | | 5-20% | | 5 | |
| | | < 5% | | ō | |
| #6 | 10 | Red Blood Cell to Plasma Ratio (Weighted I | Mean Points) of Patients Transfused >5 | 1 | 1 |
| | | Units in 1st 4 Hours (18 Mo's: 1/1/16-6/30) | 엄마 이번 것에 잘 아니는 것은 아이들을 것 것 같아요. 아이는 것에서 가슴을 가지 않는 것을 가지 않는 것이 귀엽다. | | |
| | | 10 pts: Tier 1: < 1.5 | (17) | 0-10 | I |
| | | 10 pts: Tier 2: 1.6-2.0 | | 0 10 | |
| | | 5 pts: Tier 3: 2.1-2.5 | | | |
| | | 0 pts: Tier 4: >2.5 | | | L |
| #7 | 10 | Serious Complication Rate-Trauma Service | Admits (3 years: 7/1/14.6/30/17) | | 1 |
| Π/ | 10 | Z-score: < -1 (major improvement) | Autilits (5 years. 7/1/14-0/50/17) | 10 | |
| | | Z-score: -1 to 1 or serious complications low | -outlier (average or better rate) | 7 | |
| | | Z-score: > 1 (rates of serious complications ion | | 5 | |
| #8 | 10 | Mortality Rate-Trauma Service Admits (3 y | | 2 | - |
| 10 | 10 | Z-score: < -1 (major improvement) | cuis. //1/14-0/30/1/) | 10 | |
| | | Z-score: -1 to 1 or mortality low-outlier (ave | | 7 | |
| | | 그 이번 가슴 가슴 가슴 것 같아. 편 것은 것은 것은 것에서 가슴을 알 것을 만들어야 한다. 것은 것은 것은 것을 많은 것은 | | 5 | |
| #9 | 10 | Z-score: > 1 (rates of mortality increased) Inferior Vena Cava Filter Use (All Admits) ((| Collaborativa Wido) (7/1/16 6/20/17) | 0 | + |
| #9 | 10 | 1201 2020 | oliaborative Wide) (7/1/10-6/30/17) | 10 | |
| | | Maintenance | | 10 | |
| #10 | 10 | - 1.E | | 0 | + |
| #10 | 10 | Site Specific Quality Improvement Project | Daily 2010-December 2017 | 10 | |
| | | Implemented, and met or exceeded target | d not meet target Drop | 10 | |
| | | Implemented, showed improvement, but di | u not meet taiget | 7 | |
| | 10. | Implemented, but showed no improvement | | 0 | 1 |

≥ 50% 10 37-49% 7 25-36% 5 20-24% 3 <20% 0

Summary

3 with Changes

2 Drop

Need 2 New

Open Fracture

- Define group of AIS codes
 - Femur, Tib-fib, other?
 - Record date, time, antibiotic given
 - Scoring, need all 3 of above
 - \geq 90 % patients = 10 points
 - \geq 80 % patients = 7 points
 - \geq 70 % patients = 5 points
 - < 70 % patients = 0 points</p>
 - Allow for determination of baseline % given within 60 minutes
 - New targets based on collected data

Head Injury on Anticoagulation

- Head CT date, time in anticoagulated patient
 - Anticoagulated patient, Head AIS≥1
 - Record date, time, Head CT
 - Scoring, need all 3 of above
 - \geq 90 % patients = 10 points
 - \geq 80 % patients = 7 points
 - \geq 70 % patients = 5 points
 - < 70 % patients = 0 points</p>
 - Allow for determination of baseline time to CT scan
 - New targets based on collected data

Head Injury on Anticoagulation

- Add data elements for 2018
- Collect on head injury patient with
 - Coumadin
 - NOAC
 - Plavix
 - Aspirin (Antiplatelet)
- What data to collect
 - Handout
 - Pilot with Excel
- Grow project iteratively

Site Specific Projects

Judy Mikhail, RN PhD





Unplanned ICU Admissions

Beaumont Farmington Hills

Michael Rebock, DO TMD Barb Smith, RN, TPM Cathy Levinson, RN, MCR Shauna Di Pasquo, RN, Registrar Corinna Azar, RN, Registrar

Background

- Site specific PI project for 2017
- Outlier on MTQIP and TQIP Benchmark Reports
- •
- Cohort 4 Blunt single, All ISS, All ages

Barriers

- No Intermediate Care Unit
- High population of elderly traumas
- Many with multiple comorbidities and functionally dependent

Actions Taken

- Reviewed all cases back to 2015 for trends
- Discussed at TOPIC and PIPS
- Physician review of preventable cases
- Exploring elderly guidelines/management
- Reviewing ETOH withdrawal policies

FINDINGS

- Atrial Fibrillation
- Hypoxia
- Chronic medical disease



SOLUTIONS

- Better use of respiratory therapy and high flow O2
- Better use of Rapid Response Team
- ICU Nurse Practitioner now rounds on patient the day after transfer
- Closer look at vitals 24 hours prior to transfer
- Patients converted to oral cardiac meds prior to transfer

Outcomes

| | Time-Period | | | |
|----------|-------------------------------|--|--|--|
| Dec | Date Range | | | |
| 2016 | UnadjRate | | | |
| Baseline | Numerator/Denominator | | | |
| | Num or DataPts = #Patients | | | |
| Apr | Date Range | | | |
| 2017 | UnadjRate | | | |
| | Numerator/Denominator | | | |
| | Num or DataPts = #Patients | | | |
| Aug | Date Range | | | |
| 2017 | UnadjRate | | | |
| | Numerator/Denominator | | | |
| | Num or DataPts = #Patients | | | |
| Dec | Date Range | | | |
| 2017 | UnadjRate | | | |
| Final | Numerator/Denominator | | | |
| | Num or DataPts = #Patients | | | |
| Dec | rease "By" What Percent? | | | |
| Target D | ecrease "To" <u>UnadjRate</u> | | | |



Moving Forward

- NICHE program
- Continue to work on Step-down proposal
- TCAR classes for RN's
- Continuing to review each case at daily rounds
- Monitoring trends

ED to ICU Length of Stay

Sinai Grace Hospital

Lazslo Hoesel, MD MTQIP Liaison Gwyneth Navas, RN Trauma Program Manager Melissa Keller, PA-C Trauma Physician Assistant Patricia Danhoff, Registrar Tijuan Davis, Registrar Danielle Finn, Registrar

Background

- The problem?
 - Excess LOS in ED prior to ICU admission
- How long have you had it?

– 5 years

- What are the barriers in your institution?
 - High volume trauma patients (approx 2000/year)
 - High volume of General Surgery, Neurosurgery, Vascular Surgery and Orthopedic Surgery
 - High occupancy of SICU beds
 - Staffing

Actions Taken

- What have you done to address it?
 - Tracked time from order to ED disposition
 - Met with ED/SICU nursing leadership and SICU attending's
 - Reported variances at our Trauma Systems
 Meeting

MTQIP E.D. L.O.S. Time

Outcomes

| December 2016 Baseline | |
|---------------------------|--|
| April 2017 | |

Moving Forward

- Next steps?
 - Use staffing grids to improve coverage for increased number of patients and variances including use of agency nurses
- Future actions?
 - Monitor and determine other barriers if our numbers don't continue to improve
- How will you sustain the change?
 - Continued monitoring through our monthly
 Trauma Systems Meeting

Future Directions

- Goal is decrease by the end of 2017
- The Unadjusted rate will be hours
- End goal is to meet the MTQIP average of 4 hours

Unplanned Admission to ICU

UNIVERSITY OF MICHIGAN SARA SAMBORN, MSN, RN MTQIP CLINICAL REVIEWER

Identified problems and barriers

High outlier
Associated complications
Understanding of definition
Team engagement

High Outlier

Associated Complications

PneumoniaUnplanned Intubation

Intervention

Patient list drill down
Identified risk factors
Data presented to trauma team
Faculty
Residents/Fellows
NPs and PAs
Trauma ICU and floor RNs and staff

What we know

Moving forward

2018 PI Project?
Buy in from the trauma team
Create a system to identify at risk patients

Michigan OPEN

Mike Englesbe, MD



How can we combat the opioid epidemic

Jenn Waljee

Chad Brummett Mike Englesbe




engaging patients, educating providers, protecting communities

Opioid dependence is the most significant public health threat in the United States.

How can we fix this problem

Who owns this problem


Drug Poisoning Mortality: 2014




Designed by L. Rossen, B. Bastian & Y. Chong. SOURCE: CDC/NCHS, National Vital Statistics System.

Obtained from https://blogs.cdc.gov/nchs-data-visualization/drug-poisoning-mortality/

12 STATES HAVE MORE PAINKILLER PRESCRIPTIONS THAN PEOPLE




Deaths per 100,000 population, aged 45-54



Source: "Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century", by Anne Case and Angus Deaton


*Drug-related overdoses, etc.

Economist.com



Opioid Prescribed (OME / 30 days)

45 tablets of Norco (5/325)



70 - 75% unused

Hill MV, McMahon ML, Stucke RS, Barth RJ, Jr. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. Ann Surg. 2017;265(4):709-714.

Surgeons facilitate DIVERSION






Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL. Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults. JAMA Intern Med. 2016;176(7):1027-1029.

62 Million unused pills a year in Michigan




- 1. HCUP Fast Stats. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for Healthcare Research and Quality, Rockville, MD.
- 2. HCUP Central Distributor SASD File Composition. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for Healthcare Research and Quality, Rockville, MD.

New Persistent Use



Postoperative opioid dependence happens in pediatric patients






Opioid Prescribing Guidelines: Laparoscopic Cholecystectomy








Laparoscopic Cholecystectomy



Laparoscopic Cholecystectomy




OME Total (mg)

Let's get smart about prescribing

15 Oxycodone 5 mg 1q4-6 PRN

15 Norco 5/325 mg 1q4-6 PRN

+ Tylenol AND Motrin



Some examples of recognizing excess and creating a guideline

| Procedure | Avg rx | Avg taken | Recommendation |
|-----------------------------|--------|-----------|----------------|
| Lap chole | 30 | 10 | 15 |
| Lap inguinal hernia repair | 30 | 5 | 15 |
| Open inguinal hernia repair | 30 | 10 | 15 |
| Partial mastectomy w/ SLNB | 20 | 5 | 10 |
| Partial mastectomy | 20 | 3 | 5 |



engaging patients, educating providers, protecting communities


Opioid Recovery Drives





| Total number of people | 349 | |
|---|-----------|--|
| Pills | | |
| Estimated weight of pills | 181.6 lb | |
| Estimated total number pills | 139,658.5 | |
| Opioid pills | 13,784 | |
| Most common - Hydrocodone | 5,714 | |
| Other medications of interest | | |
| Benzodiazepines and sedatives | 3,002 | |
| Anti-depressants | 6,401 | |
| Stimulants | 623 | |
| Muscle relaxants | 565 | |
| Anti-epileptics | 4,156 | |
| Additional information | | |
| Oldest opioid date (by year) | 1981 | |
| Second oldest opioid (different person) | 1985 | |
| Most common reason for opioid | Surgery | |
| | | |

Opioid Recovery Drive – May 20, 2017



https://medicine.umich.edu/dept/pain-research/pain-medication-take-back-program

14 bills in Michigan for 2017-2018

| Document | Туре | Description |
|-----------------|-------------|---|
| SB 0167 of 2017 | Senate Bill | Health occupations; physicians; physicians failing to report to Michigan automated prescription system (MAPS) prescriptions of any schedule II-V substances; require to attend certain classes, and provide for sanctions under certain circumstances. Amends secs. 16221 & 16226 of 1978 PA 368 (MCL 333.16221 & 333.16226). TIE BAR WITH: SB 0166'17 |
| SB 0218 of 2017 | Senate Bill | Appropriations; other; executive recommendation; provide for omnibus bill. Creates appropriations act. |
| SB 0236 of 2017 | Senate Bill | Health; controlled substances; prescription drug and opioid abuse commission; require to provide recommendations for the instruction of pupils on prescription opioid drug abuse. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7113a. TIE BAR WITH: SB 0237'17 |
| SB 0237 of 2017 | Senate Bill | Education; curriculum; require instruction on prescription opioid drug abuse prevention. Amends 1976 PA 451 (MCL 380.1 - 380.1852) by adding sec. 1503. TIE BAR WITH: SB 0236'17 |
| SB 0272 of 2017 | Senate Bill | Health; controlled substances; requirement for a patient or the patient's representative to sign a form when being prescribed opioids indicating that the patient has received certain information; provide for. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7303b. |
| SB 0273 of 2017 | Senate Bill | Health occupations; physicians; physicians to provide information on substance use disorder services to patients being treated for opioid-related overdoses; require. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding secs. 17019 & 17519. |
| SB 0274 of 2017 | Senate Bill | Health; controlled substances; prescription for opioids; limit, and require prescribers to prescribe an opioid antagonist under certain circumstances. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b) & adds sec. 7333b. |
| HB 4074 of 2017 | House Bill | Insurance; health insurers; abuse-deterrent opioid analgesic drug; require coverage. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406u. |
| HB 4170 of 2017 | House Bill | Health; other; physician orders for scope of treatment forms; allow. Amends sec. 20919 of 1978 PA 368 (MCL 333.20919) & adds pt. 56B & sec. 20192a. TIE BAR WITH: HB 4171'17, HB 4173'17, HB 4174'17 |
| HB 4368 of 2017 | House Bill | Appropriations; other; executive recommendation; provide for omnibus bill. Creates appropriation act. |
| HB 4403 of 2017 | House Bill | Human services; medical services; acute treatment services and clinical stabilization services for opioid addiction as a covered medical service; allow. Amends sec. 109 of 1939 PA 280 (MCL 400.109). |
| HB 4406 of 2017 | House Bill | Health; controlled substances; prescription drug and opioid abuse commission; require to provide recommendations for the instruction of pupils on prescription opioid drug abuse. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 7113a. TIE BAR WITH: HB 4407'17 |
| HB 4407 of 2017 | House Bill | Education; curriculum; health curriculum; instruction on prescription opioid drug abuse prevention; require. Amends 1976 PA 451 (MCL 380.1 - 380.1852) by adding sec. 1503. TIE BAR WITH: HB 4406'17 |
| HB 4408 of 2017 | House Bill | Health; pharmaceuticals; parental consent when prescribing a controlled substance containing an opioid; require under certain circumstances. Amends secs. 16221 & 16226 of 1978 PA 368 (MCL 333.16221 & 333.16226) & adds sec. 7303b. |



30%



)HHS

VALUE Partnerships Improving Health Care in Michigan

Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Michigan Surgical Quality Collaborative

M·TQIP

Michigan Value Collaborative

Anesthesiology Performance Improvement and Reporting Exchange

ASPI





Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association



Michigan Department of Health & Human Services

RICK SNYDER, GOVERNOR | NICK LYON, DIRECTOR

OPEN/ Opioid Prescribing Engagement Network

engaging patients, educating providers, protecting communities

Contact us



filip@umich.edu



caitham@umich.edu



cbrummet@umich.edu

englesbe@umich.edu 7349040287



engaging patients, educating providers, protecting communities

Conclusion

Evaluations

- Fill out and turn in
- Questions?
- See you in October